查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999376

腫瘤NGS市場：2026-2032年全球市場預測（按產品類型、癌症類型、技術、檢體階段、應用和最終用戶分類）

Oncology NGS Market by Product Type, Cancer Type, Technology, Sample Type, Workflow Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腫瘤學領域的次世代定序(NGS) 市值將達到 40.1 億美元，到 2026 年將成長至 45.8 億美元，到 2032 年將達到 108.5 億美元，複合年成長率為 15.27%。

主要市場統計數據
基準年 2025 40.1億美元
預計年份：2026年 45.8億美元
預測年份 2032 108.5億美元
複合年成長率 (%) 15.27%

全面概述臨床定序創新、監管進步和營運架構如何融合，從而重新定義腫瘤學的決策。

次世代定序(NGS) 已從一項實驗性技術發展成為腫瘤學研究、診斷和治療方法開發的核心支柱。高通量定序儀的引入、日益完善的生物資訊流程以及檢驗的臨床檢測方法，使得分子譜分析能夠輔助診斷、預測治療反應並監測微量殘存疾病。隨著技術的融合，檢查室和臨床團隊正在將定序應用於持續的臨床實踐中，從靶向基因panel分析到全面的EXOME和轉錄組分析，從而拓展了從患者檢體中獲取可操作資訊的範圍。

定序、資訊學和多組體學整合的技術進步如何重塑腫瘤學的診斷工作流程和臨床決策流程。

腫瘤定序領域正經歷一場變革，其驅動力來自於技術突破、數據整合以及不斷演進的臨床範式。短讀長定序平台持續最佳化成本和通量，而長讀長定序和單分子定序方法則推進了對以往難以分析的結構變異和複雜基因組區域的表徵。同時，檢測設計也從廣泛的探索性檢測轉向以臨床為中心的設計，優先關注可操作的突變和預測性生物標記物，從而能夠快速地將結果反饋到治療方法的選擇中。

為因應 2025 年關稅造成的供應鏈中斷，制定營運應對措施和籌資策略，並提高總到岸成本的透明度。

政策變革和貿易措施將對整個診斷生態系統的供應鏈、成本結構和籌資策略產生重大影響。 2025 年美國關稅措施為依賴全球生產系統和複雜組件採購的檢查室、試劑生產商和設備供應商帶來了新的挑戰。為了因應這些變化，企業領導者正在尋求供應商多元化，重新審視庫存策略，並調整物流計劃，以降低跨境成本波動和潛在交貨延遲帶來的風險。

詳細的細分分析揭示了每種產品類型、癌症類型、應用和最終用戶的不同要求，從而影響檢測開發和商業化的方法。

細分市場分析揭示了不同產品類型、癌症類型、應用領域和最終用戶所面臨的細微需求和機會。就產品類型而言，平台需要為分散式臨床檢查室的桌上型定序儀和支援大規模集中式操作的高通量定序儀進行資本規劃。試劑和耗材包括流動池、樣品製備盒和定序盒，每種產品的保存期限和低溫運輸需求各不相同。服務包括數據分析和檢體製備服務，這些服務需要根據處理量和監管要求進行規模化調整。

區域趨勢和監管差異影響定序能力、報銷模式和基礎設施投資對全球臨床部署的影響。

地理趨勢影響法律規範、報銷環境和營運模式，從而形成不同的區域優先事項，進而影響技術應用和投資。在美洲，完善的報銷機制、成熟的參考檢查室網路和活躍的臨床試驗活動正在推動臨床應用，支援集中式高通量定序和分散式診斷檢測。該地區支付方、醫療服務提供者和創新者之間的持續互動，加速了實證醫學證據的產生，同時也提高了人們對臨床效用和療效的期望。

競爭性創新、策略夥伴關係和能力整合如何推動腫瘤定序平台、試劑和服務供應商之間的差異化。

企業間的競爭與合作動態正在塑造整個腫瘤定序系統的創新路徑與服務交付模式。成熟的平台供應商持續投資於儀器性能、通量最佳化和整合軟體，以降低臨床應用門檻。同時，專業的試劑和耗材公司則專注於供應鏈韌性、檢測穩健性和跨多種儀器類型的兼容性，以適應不同的檢查室環境。服務供應商則透過提供檢驗的生物資訊解決方案、承包樣本到報告工作流程以及臨床認證的檢查室能力來減輕醫療機構的負擔，從而實現差異化競爭優勢。

制定可操作的策略重點，透過協調平台模組化、生物資訊檢驗、供應鏈彈性和相關人員合作來加速臨床部署。

行業領導者必須將技術潛力轉化為營運可行且具有臨床意義的解決方案，以維持市場地位並加速造福患者。首先，投資於平台相容性和試劑互通性可以降低客戶鎖定風險，並增強應對供應鏈中斷的能力。優先採用模組化系統結構和開放資料格式，使企業能夠在各種不同的檢查室環境中實現更廣泛的部署。

採用嚴謹的混合方法，結合對關鍵相關人員的訪談、文獻整合、案例研究和檢驗，確保獲得穩健透明的見解。

本報告透過整合多面向證據，確保了分析的穩健性和觀點。主要研究包括對實驗室負責人、臨床基因組學經理、採購負責人和行業高管進行結構化訪談，以了解實際操作情況、檢驗要求和採購標準。此外，還系統性地回顧了同行評審文獻、臨床指南、監管申報文件和公開的技術文檔，並基於已記錄的性能和臨床有效性進行技術評估。

技術成熟度、證據產生和供應鏈韌性如何結合起來，決定了腫瘤定序常規臨床應用的路徑。

總之，腫瘤特異性定序正處於關鍵時期，技術成熟度、數據整合和政策趨勢共同影響其短期發展軌跡。定序化學製程和儀器設計的進步不斷拓展分析能力，而資訊科學和結果解讀的改進則提升了其臨床意義。同時，與關稅和區域監管差異相關的供應鏈問題，也要求進行周密的營運規劃，以確保服務可靠運作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腫瘤NGS市場：依產品類型分類

  • 裝置
  • 試劑和耗材
    • 樣品製備工具包
    • 定序試劑
    • 靶向序列捕獲盒
  • 服務
    • 生物資訊學和數據分析服務
    • 臨床報告與解釋服務

第9章：按癌症類型分類的腫瘤NGS市場

  • 固體癌
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 卵巢癌
    • 惡性黑色素瘤
  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤

第10章：腫瘤NGS市場：依技術分類

  • 全基因組定序
  • 全EXOME定序
  • 標靶定序和重定序

第11章：檢體類型分類的腫瘤NGS市場

  • 組織樣本
    • 福馬林固定石蠟包埋組織
    • 新鮮冷凍組織
  • 液態生物檢體樣本
    • 電漿
    • 血清
    • 循環性腫瘤細胞

第12章：腫瘤NGS市場各階段工作流程

  • 在序列之前
  • 順序
  • 數據分析

第13章 腫瘤NGS市場：依應用領域分類

  • 臨床診斷
    • 固態腫瘤分析
    • 骨髓惡性腫瘤的分析
    • 生殖系癌易感性檢測
    • 微量殘存疾病的監測
    • 伴隨診斷
  • 調查
    • 腫瘤生物標記的發現
    • 腫瘤異質性研究
    • 抗性機制研究
  • 藥物發現
  • 液態生物檢體
    • 癌症早期發現
    • 治療反應監測
    • 復發監測

第14章 腫瘤NGS市場：依最終用戶分類

  • 學術和研究機構
  • 醫院和癌症中心
    • 腫瘤學
    • 病理檢查室
  • 臨床診斷檢查室
  • 製藥和生物技術公司
  • 合約研究機構

第15章 腫瘤NGS市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 腫瘤NGS市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 腫瘤NGS市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國腫瘤NGS市場

第19章：中國腫瘤NGS市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Burning Rock Dx
  • Creative Biogene
  • DH Life Sciences, LLC
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Genecast Group Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Myriad Genetics, Inc.
  • Oxford Nanopore Technologies plc.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer Inc.
  • Personalis, Inc.
  • Promega Corporation
  • Qiagen NV
  • seqWell
  • SOPHiA GENETICS.
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience Corporation
Product Code: MRR-3A2E844FECAB

The Oncology NGS Market was valued at USD 4.01 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 15.27%, reaching USD 10.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.01 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 10.85 billion
CAGR (%) 15.27%

A comprehensive orientation to how clinical sequencing innovations, regulatory evolution, and operational readiness are converging to redefine oncology decision making

Next-generation sequencing (NGS) has moved from an experimental capability to a core pillar of oncology research, diagnostics, and therapeutic development. The introduction of high-throughput instruments, increasingly robust bioinformatics pipelines, and validated clinical assays has enabled molecular profiling to inform diagnosis, predict therapeutic response, and monitor minimal residual disease. As technologies converge, laboratories and clinical teams are adopting sequencing across a continuum that spans targeted gene panels to comprehensive exome and transcriptome analyses, thereby expanding the scope of actionable insights derived from patient samples.

Alongside technological maturation, regulatory pathways and reimbursement conversations have become more sophisticated, prompting closer alignment between assay validation and clinical utility evidence generation. Consequently, stakeholders are investing in operational workflows, quality management systems, and data governance to ensure analytic performance translates into reproducible clinical value. This environment is creating a virtuous cycle: improved assay reliability and interpretive frameworks drive clinical adoption, which in turn generates real-world evidence that supports broader integration of NGS into standards of care.

Given the rapidly evolving science and shifting healthcare incentives, organizations must balance near-term operational readiness with strategic investments in platform flexibility, reagent supply resilience, and scalable bioinformatics. The following sections outline transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive considerations, pragmatic recommendations, and the methodological rigor underpinning the analysis.

How technological advances in sequencing, informatics, and multiomic integration are reshaping diagnostic workflows and clinical decision pathways in oncology

The oncology sequencing landscape is undergoing transformative shifts driven by technological breakthroughs, data integration, and evolving clinical paradigms. Short-read platforms have continued to optimize cost and throughput, while long-read and single-molecule approaches have advanced the characterization of structural variants and complex genomic regions that were previously refractory to analysis. Concurrently, assay design has shifted from broad, exploratory panels toward clinically focused content that prioritizes actionable variants and predictive biomarkers, enabling more rapid translation into therapeutic choices.

Informatics has emerged as a central differentiator, with cloud-native pipelines, containerized workflows, and machine learning-assisted variant interpretation improving turnaround times and interpretive consistency. These capabilities are increasingly coupled with standardized reporting frameworks that enhance cross-institutional comparability. At the same time, decentralization trends are accelerating: point-of-care and near-patient testing strategies are being piloted, complementing centralized high-throughput operations to meet diverse clinical needs and reduce time-to-result.

Finally, integration of multiomic data-including RNA sequencing and epigenetic signatures-with clinical and imaging datasets is catalyzing new biomarker discovery and refined risk stratification. As a result, laboratories and vendors are shifting resources toward modular solutions that support hybrid workflows, ensuring that investments remain relevant as diagnostic paradigms continue to evolve.

Operational responses and procurement strategies adapted to tariff-driven supply chain disruptions and increased total landed cost transparency in 2025

Policy changes and trade measures can materially affect supply chains, cost structures, and procurement strategies across the diagnostics ecosystem. Tariff actions in the United States in 2025 have introduced additional considerations for laboratories, reagent manufacturers, and instrument suppliers that rely on globalized production and complex component sourcing. These shifts have prompted operational leaders to reassess supplier diversification, inventory policies, and logistics planning to mitigate exposure to cross-border cost variability and potential delivery delays.

In response, many organizations have accelerated qualification of alternative suppliers and adjusted stocking strategies to maintain uninterrupted services. Procurement teams are increasingly specifying supplier redundancy and localized support as part of contracting criteria, while product developers are evaluating the feasibility of regionalized manufacturing or assembly to reduce tariff-related impacts. At the same time, contract negotiations and service-level agreements are being revisited to incorporate contingency clauses that address tariff volatility and customs-related disruptions.

Importantly, stakeholders are also prioritizing transparency in total landed cost calculations and scenario planning to understand how policy dynamics could influence capital procurement and recurring reagent expenditures. Through these combined responses, operators aim to preserve clinical continuity while maintaining financial predictability in an environment where trade policy represents an elevated operational risk.

Detailed segmentation insights revealing differentiated product, cancer-type, application, and end-user imperatives that shape assay development and commercialization approaches

Segment-level analysis reveals nuanced requirements and opportunity areas that vary by product type, cancer type, application, and end user. When examined through product type, platforms require capital planning for benchtop sequencers that serve decentralized clinical labs as well as high-throughput sequencers that underpin large centralized operations; reagents and consumables span flow cells, library preparation kits, and sequencing kits with distinct shelf-life and cold-chain demands; and services encompass data analysis services and sample preparation services that must scale with volume and regulatory expectations.

When viewed by cancer type, the diagnostic and therapeutic imperatives differ: breast cancer workflows emphasize hormone receptor-related signatures and copy-number analyses, colorectal cancer places a premium on microsatellite instability and tumor mutational burden assessments, hematological malignancies rely on fusion detection and clonality profiling, and lung cancer requires sensitive detection of low-frequency driver mutations. Each cancer type drives differentiated assay design, validation metrics, and clinical reporting priorities.

By application, gene panels deliver focused actionable insights and are widely used for targeted therapy selection, RNA sequencing provides expression and fusion detection that enhance variant interpretation and resistance mechanism elucidation, and whole exome sequencing supports broader discovery applications, germline-somatic differentiation, and complex biomarker development. From the perspective of end users, academic research institutes prioritize flexibility and exploratory capability; diagnostic laboratories focus on throughput, reproducibility, and regulatory compliance; hospitals integrate sequencing into clinical pathways and require operational resilience; and pharma and biotech companies leverage sequencing for trial enrollment, companion diagnostic development, and translational research. These intersecting segmentation axes inform product positioning, validation roadmaps, and commercialization strategies.

Regional dynamics and regulatory diversity shaping how sequencing capabilities, reimbursement models, and infrastructure investments influence clinical adoption globally

Geographic dynamics influence regulatory frameworks, reimbursement environments, and operational models, yielding distinct regional priorities that shape uptake and investment. In the Americas, clinical adoption is driven by established reimbursement pathways, a mature network of reference laboratories, and active clinical trial activity, which together support both centralized high-throughput sequencing and distributed diagnostic testing. Continuous interaction between payers, providers, and innovators in this region accelerates evidence generation while raising expectations for clinical validity and utility.

In Europe, Middle East & Africa, regulatory heterogeneity combined with divergent healthcare funding models fosters a mixed landscape in which national-level policy decisions and collaborative regional initiatives determine the pace of integration. Laboratories must navigate varied certification regimes and align assays with country-specific clinical guidelines. Meanwhile, stakeholders across this region emphasize harmonized data standards and interoperability to enable cross-border research and pooled evidence generation.

In the Asia-Pacific region, rapid investments in sequencing infrastructure, growing domestic reagent manufacturing, and strong clinical trial pipelines are driving significant momentum. Diverse healthcare systems and varying levels of centralized laboratory capacity create opportunities for both scalable high-throughput facilities and adaptable benchtop solutions. Across all regions, cross-border collaborations, local validation studies, and attention to regulatory alignment remain essential to accelerate the translation of sequencing into routine oncology care.

How competitive innovation, strategic partnerships, and capability consolidation are driving differentiation across platforms, reagents, and service providers in oncology sequencing

Competitive and collaborative dynamics among companies are shaping innovation pathways and service delivery across the oncology sequencing ecosystem. Established platform providers continue to invest in instrument performance, throughput optimization, and integrated software to lower barriers to clinical adoption. Meanwhile, reagent and consumable specialists are focusing on supply-chain resilience, assay robustness, and compatibility across multiple instrument types to appeal to diverse laboratory footprints. Service providers are differentiating through validated bioinformatics offerings, turn-key sample-to-report workflows, and clinically accredited laboratory capabilities that reduce burden for healthcare providers.

Strategic partnerships between technology vendors, clinical laboratories, and pharmaceutical developers are increasingly common, as co-development agreements accelerate companion diagnostic programs and enable more efficient patient stratification in therapeutic trials. Emerging companies are concentrating on niche areas such as ultra-sensitive liquid biopsy assays, multiomic panels, and AI-enhanced interpretation platforms that address unmet clinical needs. In parallel, investment activity and targeted acquisitions continue to consolidate capabilities where scale and regulatory experience deliver competitive advantage.

Across these dynamics, successful organizations are prioritizing reproducibility, regulatory readiness, and customer support infrastructure that spans training, assay validation, and post-market surveillance. These capabilities underpin trust among clinicians and payers and differentiate suppliers in a market where clinical evidence and operational reliability are decisive.

Actionable strategic priorities that align platform modularity, bioinformatics validation, supply resilience, and stakeholder engagement to accelerate clinical adoption

Industry leaders must translate technological promise into operationally viable, clinically meaningful solutions to retain market relevance and accelerate patient impact. First, investing in platform compatibility and reagent interoperability reduces customer lock-in risk and enhances resilience against supply-chain disruptions. By prioritizing modular system architectures and open-data formats, organizations can enable broader adoption across heterogeneous laboratory environments.

Second, strengthening bioinformatics and interpretation capabilities is essential. This means investing in validated pipelines, standardized variant curation frameworks, and clinically focused reporting templates that reduce time-to-action for clinicians. Equally important is the development of clinician-facing educational programs and interpretation support that contextualize genomic findings within treatment pathways.

Third, leaders should formalize supplier diversification and regionalization strategies to mitigate tariff exposure and logistics risk. This includes qualifying alternative vendors, building strategic inventory buffers, and exploring regional manufacturing or assembly where feasible. Additionally, proactive engagement with regulatory bodies and payer stakeholders will ensure that evidence generation aligns with evolving expectations for clinical utility and reimbursement.

Finally, adopting a customer-centric commercialization approach that bundles technical support, validation services, and evidence-generation partnerships will accelerate adoption. By aligning product roadmaps with clinical workflows and trial requirements, organizations can deliver solutions that are not only scientifically advanced but also operationally and economically accessible.

A rigorous mixed-methods approach combining primary stakeholder interviews, literature synthesis, case studies, and triangulation to ensure robust and transparent insights

The analysis underpinning this report combines multiple evidence streams to ensure a robust and defensible perspective. Primary research included structured consultations with laboratory directors, clinical genomics leads, procurement officers, and industry executives to capture operational realities, validation requirements, and procurement criteria. These inputs were complemented by a systematic review of peer-reviewed literature, clinical guidelines, regulatory filings, and publicly available technical documentation to ground technology assessments in documented performance and clinical relevance.

Quantitative and qualitative triangulation methods were applied to reconcile disparate data sources, while case-study analyses of representative laboratory implementations provided practical insights into workflow optimization, turnaround-time drivers, and quality-control practices. The assessment of supply-chain and tariff impacts incorporated customs rulings, trade policy analyses, and logistics expert interviews to evaluate potential operational responses and mitigation strategies.

To ensure transparency, the methodology documents data sources, interview protocols, inclusion criteria, and key assumptions, and highlights limitations such as variability in regional regulatory timelines and heterogeneity in laboratory accreditation standards. Wherever applicable, data were validated through follow-up interviews with subject-matter experts and cross-checked against technical specifications and published clinical performance metrics.

Synthesis of how technology maturation, evidence generation, and supply-chain resilience collectively determine the path to routine clinical integration of oncology sequencing

In sum, oncology-focused sequencing is at an inflection point where technical maturity, data integration, and policy dynamics collectively determine near-term trajectories. Advances in sequencing chemistry and instrument design are expanding analytic capabilities, while improvements in informatics and interpretation are enhancing clinical relevance. At the same time, tariff-related supply-chain considerations and regional regulatory heterogeneity require deliberate operational planning to sustain reliable service delivery.

Organizations that succeed will be those that couple technological leadership with disciplined operational strategies: investing in interoperable platforms and validated reagents, strengthening interpretation pipelines, securing diversified supply chains, and engaging regulators and payers early in evidence development. For clinical laboratories and healthcare providers, the imperative is to embed sequencing within reproducible workflows and quality systems that deliver timely, actionable reports. For developers and investors, the priority is to align product development with clinical utility and regulatory readiness to ensure uptake.

Ultimately, the integration of sequencing into routine oncology care will be incremental and evidence-driven. By focusing on reproducibility, clinical impact, and supply resilience, stakeholders can accelerate adoption in ways that translate scientific progress into measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology NGS Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
    • 8.2.1. Library Preparation Kits
    • 8.2.2. Sequencing Reagents
    • 8.2.3. Target Enrichment Kits
  • 8.3. Services
    • 8.3.1. Bioinformatics & Data Analysis Services
    • 8.3.2. Clinical Reporting & Interpretation Services

9. Oncology NGS Market, by Cancer Type

  • 9.1. Solid Tumors
    • 9.1.1. Breast Cancer
    • 9.1.2. Lung Cancer
    • 9.1.3. Colorectal Cancer
    • 9.1.4. Prostate Cancer
    • 9.1.5. Ovarian Cancer
    • 9.1.6. Melanoma
  • 9.2. Hematologic Malignancies
    • 9.2.1. Leukemia
    • 9.2.2. Lymphoma
    • 9.2.3. Myeloma

10. Oncology NGS Market, by Technology

  • 10.1. Whole Genome Sequencing
  • 10.2. Whole Exome Sequencing
  • 10.3. Targeted Sequencing & Resequencing

11. Oncology NGS Market, by Sample Type

  • 11.1. Tissue Samples
    • 11.1.1. Formalin-Fixed Paraffin-Embedded Tissue
    • 11.1.2. Fresh Frozen Tissue
  • 11.2. Liquid Biopsy Samples
    • 11.2.1. Plasma
    • 11.2.2. Serum
    • 11.2.3. Circulating Tumor Cells

12. Oncology NGS Market, by Workflow Stage

  • 12.1. Pre-Sequencing
  • 12.2. Sequencing
  • 12.3. Data Analysis

13. Oncology NGS Market, by Application

  • 13.1. Clinical Diagnostics
    • 13.1.1. Solid Tumor Profiling
    • 13.1.2. Hematologic Malignancy Profiling
    • 13.1.3. Germline Cancer Predisposition Testing
    • 13.1.4. Minimal Residual Disease Monitoring
    • 13.1.5. Companion Diagnostics
  • 13.2. Research
    • 13.2.1. Oncology Biomarker Discovery
    • 13.2.2. Tumor Heterogeneity Studies
    • 13.2.3. Resistance Mechanism Studies
  • 13.3. Drug Development
  • 13.4. Liquid Biopsy
    • 13.4.1. Early Cancer Detection
    • 13.4.2. Treatment Response Monitoring
    • 13.4.3. Recurrence Surveillance

14. Oncology NGS Market, by End User

  • 14.1. Academic & Research Institutions
  • 14.2. Hospitals & Cancer Centers
    • 14.2.1. Oncology Departments
    • 14.2.2. Pathology Laboratories
  • 14.3. Clinical Diagnostic Laboratories
  • 14.4. Pharmaceutical & Biotechnology Companies
  • 14.5. Contract Research Organizations

15. Oncology NGS Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Oncology NGS Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Oncology NGS Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Oncology NGS Market

19. China Oncology NGS Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Agilent Technologies, Inc.
  • 20.6. BGI Group
  • 20.7. Bio-Rad Laboratories, Inc.
  • 20.8. Burning Rock Dx
  • 20.9. Creative Biogene
  • 20.10. DH Life Sciences, LLC
  • 20.11. Eurofins Scientific S.E.
  • 20.12. Exact Sciences Corporation
  • 20.13. F. Hoffmann-La Roche Ltd
  • 20.14. Genecast Group Inc.
  • 20.15. Guardant Health, Inc.
  • 20.16. Hologic, Inc.
  • 20.17. Illumina, Inc.
  • 20.18. Invivoscribe, Inc.
  • 20.19. Myriad Genetics, Inc.
  • 20.20. Oxford Nanopore Technologies plc.
  • 20.21. Pacific Biosciences of California, Inc.
  • 20.22. PerkinElmer Inc.
  • 20.23. Personalis, Inc.
  • 20.24. Promega Corporation
  • 20.25. Qiagen N.V.
  • 20.26. seqWell
  • 20.27. SOPHiA GENETICS.
  • 20.28. Takara Bio Inc.
  • 20.29. Tecan Trading AG
  • 20.30. Thermo Fisher Scientific, Inc.
  • 20.31. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY NGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL REPORTING & INTERPRETATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL REPORTING & INTERPRETATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL REPORTING & INTERPRETATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY NGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY NGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY NGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGETED SEQUENCING & RESEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGETED SEQUENCING & RESEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGETED SEQUENCING & RESEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRE-SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRE-SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRE-SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMOR PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMOR PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMOR PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GERMLINE CANCER PREDISPOSITION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GERMLINE CANCER PREDISPOSITION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GERMLINE CANCER PREDISPOSITION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TUMOR HETEROGENEITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TUMOR HETEROGENEITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TUMOR HETEROGENEITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESISTANCE MECHANISM STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESISTANCE MECHANISM STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESISTANCE MECHANISM STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONCOLOGY NGS MARKET SIZE, BY EARLY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ONCOLOGY NGS MARKET SIZE, BY EARLY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONCOLOGY NGS MARKET SIZE, BY EARLY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TREATMENT RESPONSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TREATMENT RESPONSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TREATMENT RESPONSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RECURRENCE SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RECURRENCE SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RECURRENCE SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE,